main content start

Homepage

Latest Videos

Latest Videos

Brightcove Home Latest Listing

Breast Cancer

Prostate Cancer

Multiple Myeloma

Multiple Myeloma

Brightcove Cards Listing

Popular on MedEnrich

Popular in No name
  • Myelodysplastic Syndromes8m 45s

    Current Challenges in MDS Diagnosis and Consequences

    Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.
    non invasive mds diagnosis web based mds diagnosis tools
  • Myelodysplastic Syndromes7m 3s

    Clinical Application of Web Based Tool for Improving MDS Diagnosis

    Gradient Based Model based on 10 routinely used parameters (Age, Gender, Hb, WBC, MCV, Platelets, Neutrophils, Monocytes, Glucose, Creatinine) is now available to facilitate non-invasive diagnosis of MDS.
    mds non-invasive diagnosis
  • Breast Cancer14m 46s

    ESMO 2022 Breast Cancer Comprehensive Coverage

    View comprehensive coverage of Breast Cancer from ESMO 2022
    dose dense adjuvant chemotherapy esmo keynote -522 monarch -3 study
  • Myelodysplastic Syndromes3m 18s

    Anemia of MDS

    Anemia is common feature of MDS with 90% patients having anemia at diagnosis or initial presentation. Anemia not only impacts quality of life but is also prognostic in nature.
    anemia mds transfusion dependence
  • Breast Cancer15m 43s

    Treatment sequencing - integrating CDK4-6 inhibitors with hormonal therapy in HR+ve ,Her2 Negative Metastatic Breast Cancer

    CDK4/6 inhibitors, combined with hormonal therapy, are key in treating HR+/HER2- metastatic breast cancer. Treatment sequencing after progression focuses on personalized strategies, including SERDs, PI3K/mTOR inhibitors, and chemotherapy.
    cdk4/6 inhibitors hormonal therapy personalized treatment strategies treatment sequencing
  • Breast Cancer11m 14s

    Oral Selective Estrogen Receptor Degraders for ESR-1 Mutant Metastatic Breast Cancer

    Endocrine therapy is the mainstay in the management of patients with Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Tumor progression in ER+ve MBC could be attributed to genomic alterations such as ESR mutations.
    biomarkers esr1 mutation fulvestrant hormone receptor positive mbc serd
  • Pharmacy37m 20s

    Quality management systems in pharmacy practice

    Dr Scott Soefje, PharmD, Mayo Clinic
    Provides a perspective “Quality Management Systems in Pharmacy Practice”.
    mednrich
  • Prostate Cancer49m 18s

    Dissecting the biology of advanced prostate cancer

    Advanced prostate cancer is characterized by intricate biological changes, including genetic and epigenetic alterations, as well as shifts in cellular metabolism.
    advanced prostate cancer cellular metabolism castration-resistant prostate cancer targeted therapies improved patient care
  • Multiple-Myeloma0m 53s

    Importance of identifying High Risk Patients in Multiple Myeloma

    High risk disease is observed in 30% of Myeloma Cases. Identification of high-risk patients is important as proportion of high-risk cases increase with relapses and can lead to significant mortality.
    high risk myeloma
  • Prostate Cancer3m 41s

    Whole genome sequencing in clinical practice

    Whole Genome Sequencing (Short)
    Whole Genome Sequencing is new tool for precision medicine in metastatic castration
    precision medicine prostate cancer whole genome sequencing
  • For Pharmacist

    For Pharmacist

    Brightcove Cards Listing

    Webinars

    Webinar Cards Listing

    MedBytes

    MedBytes

    Medbytes Cards Listing
    Hi, can I help?
    Chat SupportX
    Support Team
    Hello, how can I help you today?
    Please select one of the below options.

    Find Information

    Unable to Login or Register

    Want to share feedback